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SUPPLEMENTARY METHODS AND DATA 
Screening for Macrocycles against IL-17F and IL-17A Epitopes 
For IL-17F, screens were performed using a triazole-cyclized one-bead-one-compound (OBOC) 
library of the form H2N-Pra-Cy(XXXXX)-Met-TG, where TG = TentaGel® S NH2 resin (Rapp 
Polymere), X = one of 17 L-amino acids (lacking Cys, Met, and Ile), Pra = L-propargylglycine, 
and Cy(  ) = triazole cyclization via flanking Pra and Az4 (= L-azidolysine) residues. 
Pre-clear.  Swelled library beads (500 mg) were blocked overnight with Blocking Buffer 
(25 mM Tris-HCl, 150 mM NaCl, 1% (w/v) BSA, and 0.05% (v/v) Tween-20, pH 7.6) at 4 ºC, then 
washed with Blocking Buffer three times.  A 1:10,000 dilution of Streptavidin-Alkaline 
Phosphatase (V559C, Promega) in 5 mL Blocking Buffer was added to the beads and incubated 
with gentle shaking at room temperature for 1 h.  The beads were subsequently washed with 3 x 3 
mL TBS (25 mM Tris-HCl, 150 mM NaCl, pH 7.6) (1 min ea), 3 x 3 mL 0.1 M glycine pH 2.8 wash 
buffer, 3 x 3 mL TBS, then 3 x 3 mL Alkaline Phosphatase buffer (100 mM Tris-HCl, 150 mM 
NaCl, 1 mM MgCl2, pH 9) (5 min ea).  Binding was visualized by incubating the beads in the 
presence of 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) substrate 
(S3771, Promega) for 25 min.  Purple beads indicated background binders and were removed by 
pipet and discarded.  The remaining clear beads were collected and stripped with 7.5 M guanidine 
hydrochloride pH 2.0 for 30 min, washed ten times with water, and incubated in 1-methyl-2-
pyrrolidinone (NMP) overnight to decolorize. 
Product screen with IL-17F and IL-17A epitopes.  Beads remaining from the pre-clear 
were washed with water ten times and TBS three times.  Beads were then incubated with 3 mL of 
100 µM IL-17F SynEp1 (Biotin-PEG3-FFQKPES[Az4]PPVPGGS) in TBS for 1.5 h at room 
temperature to allow for an in situ click reaction to occur.  The beads were washed with TBS ten 
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times and then incubated with 7.5 M guanidine hydrochloride pH 2.0 for 1 h to remove all IL-17F 
epitope not attached covalently to the beads.  These beads were washed with TBS ten times and 
re-blocked with Blocking Buffer for 2 h.  A 1:10,000 dilution of Streptavidin-Alkaline Phosphatase 
in 5 mL Blocking Buffer was added for 1 h to detect the presence of IL-17F epitope clicked to 
beads.  The beads were subsequently washed with 3 x 3 mL TBS (1 min ea), 3 x 3 mL 0.1 M 
glycine pH 2.8 wash buffer, 3 x 3 mL TBS, then 3 x 3 mL Alkaline Phosphatase (pH 9) buffer (5 
min ea).  After this, the beads were developed with BCIP/NBT for 25 min as outlined in the pre-
clear.  Purple epitope-conjugated hit beads were selected by pipet and saved.  These hits (25 total:  
5 dark purple, 20 medium to light purple) were treated with 7.5 M guanidine hydrochloride pH 
2.0 for 30 min to remove attached streptavidin, washed ten times with water, and incubated in 
NMP overnight to decolorize. 
This screening protocol was repeated with IL-17F SynEp2 (Biotin-PEG3-GI[Az4] 
NENQRVS).  From this screen, 98 epitope-conjugated hits beads were selected (50 dark purple, 
48 medium to light purple). 
For IL-17A SynEp3 (Biotin-PEG3-PNSEDKNFPRTVMVNL[Az4]), the same screening 
protocol was performed with a triazole-cyclized OBOC library of D-amino acids.  From this screen, 
three epitope-conjugated hits beads were selected.  Due to the small number of hit beads identified, 
no further IL-17A screens were performed.   
Target screen with His-tagged IL-17F protein.  The hits isolated from the IL-17F 
product screens were washed with water ten times and stored in TBS at 4 ºC.  These beads were 
transferred to a Corning® 8162 Costar® Spin-X® centrifuge tube filter (cellulose acetate 
membrane) and incubated with Blocking Buffer for 3 h at room temperature.  The beads were 
rinsed three times with Blocking Buffer and then incubated with 150 nM of full-length His-tagged 
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IL-17F protein (ab167911, Abcam) in Blocking Buffer (preparation:  0.5 µL His-tagged IL-17F 
protein in 200 µL Blocking Buffer) for 1 h at room temperature.  The beads were washed three 
times with Blocking Buffer and then incubated with 500 µL of 1:10,000 Anti-6X His tag® 
antibody [HIS-1] (Alkaline Phosphatase-conjugated) (ab49746, Abcam) in Blocking Buffer for 1 
h at room temperature.  The beads were subsequently washed with 3 x 500 µL Blocking Buffer, 3 
x 500 µL TBS, then 3 x 500 µL Alkaline Phosphatase (pH 9) buffer (centrifuging at 7000 rpm for 
30 s after each wash).  After this, the beads were developed with BCIP/NBT for 10 min.  Purple 
hit beads bound to IL-17F protein were selected by pipet and saved.  For SynEp1, 20 beads were 
purple indicating binding to both the IL-17 epitope and protein, while 5 were clear indicating 
no binding to IL-17F protein.  For SynEp2, 53 beads were purple indicating binding to both the 
IL-17 epitope and protein, while 40 were clear indicating no binding to IL-17F protein.  These 
target hits were treated with 7.5 M guanidine hydrochloride pH 2.0 for 30 min to remove bound 
proteins, washed ten times with water, and incubated in NMP overnight to decolorize. 
Target screen with His-tagged IL-17F protein in diluted human serum.  The hits 
isolated from the IL-17F target screens were washed with water ten times.  These beads were 
incubated with Blocking Buffer for 7 h in a Corning® 8162 Costar® Spin-X® centrifuge tube 
filter (cellulose acetate membrane).  The beads were rinsed three times with Blocking Buffer and 
then incubated with 150 nM of full-length His-tagged IL-17F protein (ab167911, Abcam) in 
Blocking Buffer containing 2% (v/v) human serum (HS-30, Omega Scientific) for 1 h at room 
temperature (preparation:  1.25 µL His-tagged IL-17F protein + 10 µL filtered serum + 490 µL 
Blocking Buffer).  Note:  Before the screen, particulate matter was removed from serum by 
centrifugation (7000 rpm, 30 s) using a Corning® 8162 Costar® Spin-X® tube filter.  The beads 
were washed three times with Blocking Buffer and then incubated with 500 µL of 1:10,000 Anti-
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6X His tag® antibody [HIS-1] (Alkaline Phosphatase-conjugated) (ab49746, Abcam) in Blocking 
Buffer for 1 h at room temperature.  The beads were subsequently washed with 3 x 500 µL 
Blocking Buffer, 3 x 500 µL TBS, then 3 x 500 µL Alkaline Phosphatase (pH 9) buffer 
(centrifuging at 7000 rpm for 30 s after each wash).  After this, the beads were developed with 
BCIP/NBT for 10 min.  Purple hit beads were selected by pipet and saved.  The 2 hits (SynEp1) 
and 23 hits (SynEp2) whose binding to IL-17F protein was unperturbed by serum proteins were 
treated with 7.5 M guanidine hydrochloride pH 2.0 for 30 min to remove bound proteins, washed 
ten times with water, and incubated in NMP overnight to decolorize.  The hits were finally washed 
with water ten times.  The SynEp1 hits were subjected to sequencing analysis.  For the SynEp2 
hits, the target screen was repeated with 5% (v/v) human serum.  Re-screening with an increased 
background of serum proteins resulted in 6 hits (SynEp2) that were subsequently decolorized and 
subjected to sequencing analysis.  
Hit sequencing was performed via Edman degradation.  For the SynEp1 and SynEp2 hits, 
the Edman sequencer was unable to distinguish between 1) residues K (lysine) and L (leucine), 
and 2) residues Q (glutamine) and T (threonine).  IL-17F sequencing results are shown in Tables 
S1 and S2 including the K/L and Q/T variants.  IL-17A sequencing results are shown in Table S3. 
 
Table S1. Sequences of macrocyclic peptide hits identified against IL-17F SynEp1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x2 x3 x4 x5 x6 
hit1 
F Y K T H 
F Y K Q H 
F Y L T H 
F Y L Q H 
x2 x3 x4 x5 x6 
hit2 
R R A T S 
R R A Q S 
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Table S2. Sequences of macrocyclic peptide hits identified against IL-17F SynEp2. 
  
x2 x3 x4 x5 x6 
hit1 
K Y G E V 
L Y G E V 
 
x2 x3 x4 x5 x6 
hit2 
V H K S G 
V H L S G 
 
x2 x3 x4 x5 x6 
hit3 
Q K H G P 
T K H G P 
Q L H G P 
T L H G P 
 
 
 
 
 
x2 x3 x4 x5 x6 
hit4 
Y D L Q R 
Y D L T R 
Y D K Q R 
Y D K T R 
x2 x3 x4 x5 x6 
hit5 
K K G W P 
K L G W P 
L K G W P 
L L G W P 
x2 x3 x4 x5 x6 
hit6 
R S Y N L 
R S Y N K 
 
Table S3. Sequences of macrocyclic peptide hits identified against IL-17A SynEp3. 
x2 x3 x4 x5 x6 
hit1 r h f r l 
hit2 n r f f f 
hit3 r k h y h 
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Characterization of Synthetic Epitopes (SynEps) 
Figure S1. (A) Structure and (B) mass spectrum of IL-17F SynEp1. 
Sequence: Biotin-PEG3-FFQKPES[Az4]PPVPGGS.  This epitope is substituted with Az4 at Cys-
48 and appended with an N‐terminal Biotin-PEG3 label.  MALDI-TOF MS (m/z): calcd. for 
C99H151N25O27S (M+H) 2155.09; found (M+H+O) = 2171.23. 
 
A. 
 
 
B. 
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Figure S2. (A) Structure and (B) mass spectrum of IL-17F SynEp2. 
Sequence: Biotin-PEG3-GI[Az4]NENQRVS.  This epitope is substituted with Az4 at Ile-62 and 
appended with an N‐terminal Biotin-PEG3 label.  MALDI-TOF MS (m/z): calcd. for 
C64H109N23O22S (M+H) 1584.78; found (M+H+O) = 1600.69. 
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Figure S3. (A) Structure and (B) mass spectrum of IL-17A SynEp3. 
Sequence: Biotin-PEG3-PNSEDKNFPRTVMVNL[Az4].  This epitope is appended with Az4 at 
the C-terminus and has an N‐terminal Biotin-PEG3 label.  MALDI-TOF MS (m/z): calcd. for 
C104H169N31O32S2 (M+H) 2429.20; found 2429.73. 
 
A. 
 
 
B. 
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Characterization of Epitope-Targeted Peptide Ligands 
Figure S4. (A) Structure and (B) mass spectrum of biotinylated LF1. 
Sequence: Cy(RRATS)-PEG3-biotin.  This ligand is appended with a C‐terminal PEG3-biotin 
label.  MALDI-TOF MS (m/z): calcd. for C53H94N20O14S (M+H) 1267.50; found 1268.60. 
 
A. 
 
 
B.  
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Figure S5. (A) Structure and (B) mass spectrum of 5-FITC-tagged LF1. 
Sequence: 5-FITC-β-Ala-Cy(RRATS).  This ligand is appended with an N‐terminal 5-FITC label.  
MALDI-TOF MS (m/z): calcd. for C57H75N19O15S (M+H) 1298.54; found 1299.47. 
 
A. 
 
 
B. 
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Figure S6. (A) Structure and (B) mass spectrum of biotinylated LF2. 
Sequence: Biotin-PEG3-Cy(RSYNK).  This ligand is appended with an N‐terminal Biotin-PEG3 
label.  MALDI-TOF MS (m/z): calcd. for C57H91N19O16S (M+H) 1330.52; found 1331.06. 
 
A. 
 
 
B. 
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Figure S7. (A) Structure and (B) mass spectrum of 5-FITC-tagged LF2. 
Sequence: 5-FITC-β-Ala-Cy(RSYNK).  This ligand is appended with an N‐terminal 5-FITC label.  
MALDI-TOF MS (m/z): calcd. for C63H78N18O16S (M+H) 1375.56; found 1376.40. 
 
A. 
 
 
B. 
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Figure S8. (A) Structure and (B) mass spectrum of biotinylated LA3. 
Sequence: Biotin-PEG3-Cy(rhfrl).  This ligand is appended with an N‐terminal Biotin-PEG3 label.  
MALDI-TOF MS (m/z): calcd. for C62H98N22O13S (M+H) 1391.74; found 1392.36. 
 
A. 
 
 
B. 
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Figure S9. (A) Structure and (B) mass spectrum of LF1 single-alanine mutant R1A (ARATS). 
Sequence: Cy(ARATS)-PEG3-biotin.  This ligand is appended with a C‐terminal PEG3-biotin 
label.  MALDI-TOF MS (m/z): calcd. for C50H87N17O14S (M+H) 1182.40; found 1183.26. 
 
A. 
 
 
B.  
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Figure S10. (A) Structure and (B) mass spectrum of LF1 single-alanine mutant R2A 
(RAATS). 
Sequence: Cy(RAATS)-PEG3-biotin.  This ligand is appended with a C‐terminal PEG3-biotin 
label.  MALDI-TOF MS (m/z): calcd. for C50H87N17O14S (M+H) 1182.40; found 1184.20. 
 
A. 
 
 
B.  
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Figure S11. (A) Structure and (B) mass spectrum of LF1 single-alanine mutant T4A 
(RRAAS). 
Sequence: Cy(RRAAS)-PEG3-biotin.  This ligand is appended with a C‐terminal PEG3-biotin 
label.  MALDI-TOF MS (m/z): calcd. for C52H92N20O13S (M+H) 1237.48; found 1239.37. 
 
A. 
 
 
B.  
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Figure S12. (A) Structure and (B) mass spectrum of LF1 single-alanine mutant S5A 
(RRATA). 
Sequence: Cy(RRATA)-PEG3-biotin.  This ligand is appended with a C‐terminal PEG3-biotin 
label.  MALDI-TOF MS (m/z): calcd. for C53H94N20O13S (M+H) 1251.50; found 1253.17. 
 
A. 
 
 
B.  
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Figure S13. (A) Structure and (B) mass spectrum of LF1 double-alanine mutant R1A/R2A 
(AAATS). 
Sequence: Cy(AAATS)-PEG3-biotin.  This ligand is appended with a C‐terminal PEG3-biotin 
label.  MALDI-TOF MS (m/z): calcd. for C47H80N14O14S (M+H) 1097.29; found 1099.18. 
 
A. 
 
 
B. 
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Figure S14. (A) Structure and (B) mass spectrum of LF1 double-alanine mutant R1A/S5A 
(ARATA). 
Sequence: Cy(ARATA)-PEG3-biotin.  This ligand is appended with a C‐terminal PEG3-biotin 
label.  MALDI-TOF MS (m/z): calcd. for C50H87N17O13S (M+H) 1166.40; found 1167.98. 
 
A. 
 
 
B.  
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Figure S15. (A) Structure and (B) mass spectrum of LF2 single-alanine mutant R1A 
(ASYNK). 
Sequence: Biotin-PEG3-Cy(ASYNK).  This ligand is appended with an N‐terminal Biotin-PEG3 
label.  MALDI-TOF MS (m/z): calcd. for C54H84N16O16S (M+H) 1245.41; found 1246.40. 
 
A. 
 
 
B.  
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Figure S16. (A) Structure and (B) mass spectrum of LF2 single-alanine mutant S2A 
(RAYNK). 
Sequence: Biotin-PEG3-Cy(RAYNK).  This ligand is appended with an N‐terminal Biotin-PEG3 
label.  MALDI-TOF MS (m/z): calcd. for C57H91N19O15S (M+H) 1314.52; found 1315.72. 
 
A. 
 
 
B.  
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Figure S17. (A) Structure and (B) mass spectrum of LF2 single-alanine mutant Y3A 
(RSANK). 
Sequence: Biotin-PEG3-Cy(RSANK).  This ligand is appended with an N‐terminal Biotin-PEG3 
label.  MALDI-TOF MS (m/z): calcd. for C51H87N19O15S (M+H) 1238.42; found 1243.25. 
 
A. 
 
 
B.  
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Figure S18. (A) Structure and (B) mass spectrum of LF2 single-alanine mutant N4A 
(RSYAK). 
Sequence: Biotin-PEG3-Cy(RSYAK).  This ligand is appended with an N‐terminal Biotin-PEG3 
label.  MALDI-TOF MS (m/z): calcd. for C56H90N18O15S (M+H) 1287.49; found 1288.25. 
 
A. 
 
 
B.  
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Figure S19. (A) Structure and (B) mass spectrum of LF2 single-alanine mutant K5A 
(RSYNA). 
Sequence: Biotin-PEG3-Cy(RSYNA).  This ligand is appended with an N‐terminal Biotin-PEG3 
label.  MALDI-TOF MS (m/z): calcd. for C54H84N18O16S (M+H) 1273.42; found 1274.50. 
 
A. 
 
 
B.  
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Figure S20. (A) Structure and (B) mass spectrum of LF2 double-alanine mutant R1A/K5A 
(ASYNA). 
Sequence: Biotin-PEG3-Cy(ASYNA).  This ligand is appended with an N‐terminal Biotin-PEG3 
label.  MALDI-TOF MS (m/z): calcd. for C51H77N15O16S (M+H) 1188.31; found 1190.23. 
 
A. 
 
 
B.  
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Figure S21. (A) Structure and (B) mass spectrum of LF2 double-alanine mutant S2A/K5A 
(RAYNA). 
Sequence: Biotin-PEG3-Cy(RAYNA).  This ligand is appended with an N‐terminal Biotin-PEG3 
label.  MALDI-TOF MS (m/z): calcd. for C54H84N18O15S (M+H) 1257.42; found 1259.03. 
 
A. 
 
 
B.  
 
 
  
29 
 
 
Figure S22. (A) Structure and (B) mass spectrum of biligand with PEG1 linker. 
Sequence: Biotin-PEG3-Cy(RSYNK)-PEG1-Cy(RRATS).  This ligand is appended with an N‐
terminal Biotin-PEG3 label.  MALDI-TOF MS (m/z): calcd. for C94H154N36O27S (M+H) 2252.15; 
found 2252.53. 
 
A. 
 
 
B. 
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Figure S23. (A) Structure and (B) mass spectrum of biligand with PEG2 linker. 
Sequence: Biotin-PEG3-Cy(RSYNK)-PEG2-Cy(RRATS).  This ligand is appended with an N‐
terminal Biotin-PEG3 label.  MALDI-TOF MS (m/z): calcd. for C96H158N36O28S (M+H) 2296.18; 
found 2296.61. 
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Figure S24. Characterization of biotinylated biligand with PEG3 linker, Bi-LF. 
Sequence: Biotin-PEG3-Cy(RSYNK)-PEG3-Cy(RRATS).  This ligand is appended with an N‐
terminal Biotin-PEG3 label.  MALDI-TOF MS (m/z): calcd. for C98H162N36O29S (M+H) 2340.20; 
found 2340.26.  (A) Structure.  (B) Mass spectrum. 
 
A. 
 
 
B. 
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Figure S25. Characterization of 5-FITC-tagged biligand with PEG3 linker, Bi-LF. 
Sequence: 5-FITC-β-Ala-Cy(RSYNK)-PEG3-Cy(RRATS).  This ligand is appended with an N‐
terminal 5-FITC label.  MALDI-TOF MS (m/z): calcd. for C104H149N35O29S (M+H) 2385.10; 
found 2387.66.  (A) Structure.  (B) Mass spectrum. 
 
A. 
 
 
B. 
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Figure S26. (A) Structure and (B) mass spectrum of biligand with PEG4 linker. 
Sequence: Biotin-PEG3-Cy(RSYNK)-PEG4-Cy(RRATS).  This ligand is appended with an N‐
terminal Biotin-PEG3 label.  MALDI-TOF MS (m/z): calcd. for C100H166N36O30S (M+H) 2384.23; 
found 2384.24. 
 
A. 
 
 
B. 
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Figure S27. (A) Structure and (B) mass spectrum of biligand with PEG5 linker. 
Sequence: Biotin-PEG3-Cy(RSYNK)-PEG5-Cy(RRATS).  This ligand is appended with an N‐
terminal Biotin-PEG3 label.  MALDI-TOF MS (m/z): calcd. for C102H170N36O31S (M+H) 2428.26; 
found 2428.98. 
 
A. 
 
 
B. 
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Figure S28. (A) Structure and (B) mass spectrum of Bi-LS. 
Sequence: Biotin-PEG3-Cy(rSYNk)-PEG3-Cy(rrATS).  This ligand contains strategic substitution 
of the trypsin-sensitive amino acids with D-amino acids and is appended with an N‐terminal Biotin-
PEG3 label.  MALDI-TOF MS (m/z): calcd. for C98H162N36O29S (M+H) 2340.20; found 2340.47. 
 
A. 
 
 
B. 
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Figure S29. (A) Structure and (B) mass spectrum of Bi-LG. 
Sequence: Biotin-PEG3-Cy(rsynk)-PEG3-Cy(rrats).  This ligand contains global substitution of D-
amino acids and is appended with an N‐terminal Biotin-PEG3 label.  MALDI-TOF MS (m/z): 
calcd. for C98H162N36O29S (M+H) 2340.20; found 2341.05. 
 
A. 
 
 
B. 
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Figure S30. Sequences, structures, and mass spectrum of His-tagged IL-17F SynEp1 
peptides.  To determine the orientation of macrocycle binding to IL-17F SynEp1, this epitope was 
re-synthesized with a His6 assay handle, C48S substitution instead of a click handle, and strategic 
scrambling of the sequences either N-terminal or C-terminal to C48S.  The scrambled amino acids 
are shown in italics. 
 
1) Sequence: His6-PEG3-SQFEKFPSPPVPGGS (scrambled N-terminal to click handle). 
 
 
 
2) Sequence: His6-PEG3-FFQKPESSPVSPGPG (scrambled C-terminal to click handle). 
 
 
 
MALDI-TOF MS (m/z): calcd. for C116H163N37O31 (M+H) 2571.23; found 2571.57. 
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Figure S31. Solid-phase synthesis of biotinylated Bi-LF.  Amino acids are shown in one-letter 
code, with L-amino acids in uppercase and D-amino acids in lowercase. Reagents and conditions: 
(a) standard Fmoc/HBTU chemistry; (b) copper(I) iodide (1.5 eq.) and L-ascorbic acid (5 eq.) in 
4:1 NMP:piperidine, overnight; (c) 5% (w/v) sodium diethyldithiocarbamate trihydrate and 5% 
(v/v) DIEA in NMP for 5 min, followed by thorough washes with NMP; (d) Fmoc-NH-PEG3-
CH2COOH (2 eq.), HATU (1.9 eq.), DIEA (5 eq.), 2 h; (e) standard Fmoc/HBTU chemistry; (f) 
copper(I) iodide (1.5 eq.) and L-ascorbic acid (5 eq.) in 4:1 NMP:piperidine, overnight; (g) 5% 
(w/v) sodium diethyldithiocarbamate trihydrate and 5% (v/v) DIEA in NMP for 5 min, followed 
by thorough washes with NMP; (h) TFA/H2O/TIS/DODT (92.5/2.5/2.5/2.5) for 2 h, followed by 
ether precipitation. 
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Peptide Synthesis 
SynEps and epitope-targeted peptide ligands were synthesized on Rink amide resin using 
Fmoc-based solid-phase synthesis on either a Titan 357 automated peptide synthesizer 
(AAPPTEC) or Liberty 1 microwave peptide synthesizer (CEM Corporation).  After acidic 
deprotection and resin cleavage, peptides were purified on a preparative scale Shimadzu HPLC 
with a reverse-phase C18 column (Phenomenex).  All peptides were analyzed for the correct mass 
using matrix-assisted laser-desorption/ionization (MALDI) time-of-flight (TOF) mass 
spectrometry (MS) with a Bruker ultrafleXtreme instrument.  Peptides were lyophilized to a 
powder for long‐term storage.  Concentrated peptide stocks were made by dissolving powder in 
DMSO and measuring the A280 absorbance via Nanodrop to determine the concentration. 
Binding Assays 
Enzyme-linked immunosorbent assay (ELISA).  A black 96-well NeutrAvidin Coated 
High Binding Capacity plate (15510, Pierce) was coated with 2 µM biotinylated macrocyclic 
peptide ligand in TBS (25 mM Tris-HCl, 150 mM NaCl, pH 7.6) for 2 h at room temperature.  
Biotinylated monoclonal anti-IL17F (TA319597, Origene) was coated at 4 µg/mL in TBS as a 
control.  The plate was aspirated and then washed with TBS (5 ×) and Wash Buffer (0.05% (v/v) 
Tween-20 in PBS, 1 ×).  Full-length His-tagged IL-17F protein (ab167911, Abcam) was serially 
diluted in Wash Buffer (from 800 to 0 nM) and incubated in the designated microwells for 90 min 
at room temperature.  Microwells were aspirated and then washed with Wash Buffer (10 ×).  To 
detect the bound IL-17F protein, Alkaline Phosphatase (AP)-conjugated Anti-6X His tag® 
antibody [HIS-1] (ab49746, Abcam) was prepared at 1:10,000 dilution and added to the microwells 
for 1 h at room temperature.  The plate was aspirated and washed with Wash Buffer (11 ×).  
AttoPhos® AP Fluorescent Substrate System (S1000, Promega) was employed to develop the 
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microwells.  Using an excitation wavelength of 430 nm, fluorescent emission at 535 nm was 
recorded by Beckman Coulter DTX880 multimode microplate reader.  Titration curves were fit 
using a four-parameter regression curve fitting program (Origin 8.5) to determine EC50 values.  
The same protocol was employed to characterize the binding affinities of anti-IL-17A macrocyclic 
peptide ligands using His-tagged IL-17A (ab166882, Abcam).  Biotinylated monoclonal anti-
IL17A (TA700015, Origene) was used as a control. 
Point ELISA (IL-17F vs. IL-17A selectivity assay).  A black 96-well NeutrAvidin 
Coated High Binding Capacity plate (15510, Pierce) was coated with 2 µM biotinylated 
macrocyclic peptide ligand in TBS (pH 7.6) for 2 h at room temperature.  The plate was aspirated 
and then washed with TBS (5 ×) and Wash Buffer (0.05% (v/v) Tween-20 in PBS, 1 ×).  Full-
length His-tagged IL-17F (ab167911, Abcam) and IL-17A (ab166882, Abcam) proteins were 
prepared at 100 and 10 nM in Wash Buffer and incubated in the designated microwells for 90 min 
at room temperature.  Microwells were aspirated and then washed with Wash Buffer (10 ×).  To 
detect the bound IL-17F and IL-17A proteins, Alkaline Phosphatase (AP)-conjugated Anti-6X His 
tag® antibody [HIS-1] (ab49746, Abcam) was prepared at 1:10,000 dilution and added to the 
microwells for 1 h at room temperature.  The plate was aspirated and washed with Wash Buffer 
(11 ×).  AttoPhos® AP Fluorescent Substrate System (S1000, Promega) was employed to develop 
the microwells.  Using an excitation wavelength of 430 nm, fluorescent emission at 535 nm was 
recorded by Beckman Coulter DTX880 multimode microplate reader. 
Assay to determine orientation of macrocycle binding to IL-17F SynEp1.  A black 96-
well NeutrAvidin Coated High Binding Capacity plate (15510, Pierce) was coated with 2 µM 
biotinylated macrocyclic peptide ligand in TBS (pH 7.6) for 2 h at room temperature.  Biotinylated 
monoclonal anti-IL17F (TA319597, Origene) was coated at 4 µg/mL in TBS as a control.  The 
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plate was aspirated and then washed with TBS (5 ×) and Wash Buffer (0.05% (v/v) Tween-20 in 
PBS, 1 ×).  Chemically synthesized His-tagged IL-17F epitopes were prepared at 2 µM in Wash 
Buffer and incubated in the designated microwells for 90 min at room temperature.  Wash Buffer 
without epitope was added as a control.  Microwells were aspirated and subsequently washed with 
Wash Buffer (10 ×).  To detect the bound IL-17F epitopes, Alkaline Phosphatase (AP)-conjugated 
Anti-6X His tag® antibody [HIS-1] (ab49746, Abcam) was prepared at 1:10,000 dilution and 
added to the microwells for 1 h at room temperature.  The plate was aspirated and washed with 
Wash Buffer (11 ×).  AttoPhos® AP Fluorescent Substrate System (S1000, Promega) was 
employed to develop the microwells.  Using an excitation wavelength of 430 nm, fluorescent 
emission at 535 nm was recorded by Beckman Coulter DTX880 multimode microplate reader.  
Data are shown after subtraction of the no-epitope background. 
Fluorescence polarization to determine binding affinities in solution.  To conduct the 
fluorescence polarization experiments, LF1, LF2, and Bi-LF were synthesized with fluorescein 5-
isothiocyanate (5-FITC; 204607, ChemPep) coupled to the N-terminus of each ligand.  
Experimental samples were generated by diluting human recombinant IL-17F with 50 nM of 5-
FITC-tagged ligands in 0.1% bovine serum albumin (BSA) in PBS.  These solutions were then 
pipetted into a black 96-well Flat Bottom Polystyrene NBS Microplate (3991, Corning).  The plate 
was then incubated at 25 °C for 30 min.  Using the excitation wavelength of 485 nm, polarized 
emission at 535 nm was recorded by Beckman Coulter DTX880 multimode plate reader.  Titration 
curves were fit using a four-parameter regression curve fitting program (Origin 8.5) to determine 
the KD values. 
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Point ELISA (serum selectivity assay).  A black 96-well NeutrAvidin Coated High 
Binding Capacity plate was coated with biotinylated LF1, LF2, and Bi-LF.  Human serum (HS-30, 
Omega Scientific) was centrifuged at 13,000 rpm for 10 min at 4 °C, and the supernatant was 
utilized in an ELISA.  Full-length His-tagged IL-17F (ab167911, Abcam) protein was prepared at 
100 nM in Wash Buffer with 0.1%, 1%, 10%, 25%, 50%, and 100% human serum, and incubated 
in the designated microwells for 90 min at room temperature.  To detect the bound IL-17F protein, 
a 1:10,000 dilution of Alkaline Phosphatase (AP)-conjugated Anti-6X His tag® antibody [HIS-1] 
(ab49746, Abcam) and AttoPhos® AP Fluorescent Substrate System (S1000, Promega) were 
employed.  The resulting fluorescence was measured in a Beckman Coulter DTX880 multimode 
plate reader (excitation at 430 nm, emission at 535 nm). 
 
Figure S32. ELISA curves comparing the biotinylated macrocycles and anti-IL-17F mAb. 
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Figure S33. Point ELISAs for IL-17F protein against the (A) macrocycles LF1, LF2, and (B) 
biligand Bi-LF in human serum solutions (% v/v). 
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Figure S34. ELISA curves comparing the biotinylated biligands Bi-LS and Bi-LG. 
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